Who are Interferon Alfa and CCI-779's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/interferon-alfa-and-cci-779.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Interferon Alfa and CCI-779 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interferon Alfa and CCI-779 (Interferon Alfa and CCI-779) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination immunotherapy and mTOR inhibitor. Area: Oncology.

phase 3 Combination immunotherapy and mTOR inhibitor Interferon alfa receptor; mTOR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Interferon Alfa and CCI-779 (Interferon Alfa and CCI-779) — Pfizer. This combination uses interferon alfa to enhance immune activation while CCI-779 (temsirolimus) inhibits mTOR to suppress tumor cell proliferation and promote apoptosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Interferon Alfa and CCI-779 TARGET	Interferon Alfa and CCI-779	Pfizer	phase 3	Combination immunotherapy and mTOR inhibitor	Interferon alfa receptor; mTOR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination immunotherapy and mTOR inhibitor class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Interferon Alfa and CCI-779 — Competitive Intelligence Brief. https://druglandscape.com/ci/interferon-alfa-and-cci-779. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab